Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Hisamitsu Pharmaceutical Co ( (JP:4530) ).
Hisamitsu Pharmaceutical’s board of directors has endorsed a management buyout led by TAIYO KOSAN CO., INC., a company 100% owned by Hisamitsu President and CEO Kazuhide Nakatomi, and expressed support for a proposed tender offer for the company’s common stock, share acquisition rights and ADRs. The board is recommending that shareholders tender their shares into the offer and that ADR holders first convert their receipts into underlying shares before participating, while leaving it to individual holders to decide whether to tender share acquisition rights; the decision is made on the premise that Hisamitsu’s stock will be delisted following the transaction, marking a shift from public to private ownership that could significantly reshape its capital structure and governance and concentrate control with existing management.
The most recent analyst rating on (JP:4530) stock is a Buy with a Yen4677.00 price target. To see the full list of analyst forecasts on Hisamitsu Pharmaceutical Co stock, see the JP:4530 Stock Forecast page.
More about Hisamitsu Pharmaceutical Co
Hisamitsu Pharmaceutical Co., Inc. is a Japan-based pharmaceutical company listed on the Tokyo, Nagoya and Fukuoka stock exchanges, known for developing and marketing prescription and over-the-counter medicines, particularly topical patches, for domestic and international markets. The company operates in a highly regulated healthcare sector and its shares are widely held by institutional and individual investors in Japan and overseas.
Average Trading Volume: 183,723
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen328.3B
For an in-depth examination of 4530 stock, go to TipRanks’ Overview page.